Reliability and validity of proxy-SSPedi and mini-SSPedi in pediatric patients 2-7 years receiving cancer treatments
Abstract Background Symptom Screening in Pediatrics Tool (SSPedi) was developed for symptom screening by children 8-18 years. Objectives were to evaluate the reliability and validity of proxy-SSPedi and self-report mini-SSPedi for younger children. Methods This multi-center study enrolled guardians...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-07-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-022-09814-8 |
| _version_ | 1828186262395158528 |
|---|---|
| author | Deborah Tomlinson L. Lee Dupuis Donna L. Johnston Susan Kuczynski Serina Patel Tal Schechter Emily Vettese Mark Mairs George A. Tomlinson Lillian Sung |
| author_facet | Deborah Tomlinson L. Lee Dupuis Donna L. Johnston Susan Kuczynski Serina Patel Tal Schechter Emily Vettese Mark Mairs George A. Tomlinson Lillian Sung |
| author_sort | Deborah Tomlinson |
| collection | DOAJ |
| description | Abstract Background Symptom Screening in Pediatrics Tool (SSPedi) was developed for symptom screening by children 8-18 years. Objectives were to evaluate the reliability and validity of proxy-SSPedi and self-report mini-SSPedi for younger children. Methods This multi-center study enrolled guardians of children 2-7 years receiving cancer treatments (proxy-SSPedi) and their children 4-7 years (mini-SSPedi). The two populations were: (1) More symptomatic group where children were receiving active cancer treatment and were in hospital or clinic for four consecutive days; and (2) Less symptomatic group where children were receiving maintenance therapy for acute lymphoblastic leukemia or had completed cancer therapy. Proxy-SSPedi or mini-SSPedi were completed with measures of mucositis, nausea, pain, quality of life and overall symptoms. Respondents in the more symptomatic group repeated proxy-SSPedi/mini-SSPedi and a global symptom change scale 3 days later. Results There were 402 guardians and 326 children included in the analysis. Test re-test reliability of proxy-SSPedi showed intraclass correlation coefficient (ICC) 0.83 (95% confidence interval (CI) 0.72-0.90). Mean difference in proxy-SSPedi between more and less symptomatic groups was 9.7 (95% CI 8.3-11.1). Proxy-SSPedi was responsive to change and hypothesized relationships between measures were observed. With a priori threshold ≥0.6, inter-rater ICC among all dyads and those 6-7 years were 0.54 (95% CI 0.45-0.62) and 0.62 (95% CI 0.50-0.71) respectively. Among participating children, other hypothesized reliability and validity thresholds were generally met. Conclusions Proxy-SSPedi is reliable, valid and responsive in children 2-7 years old receiving cancer treatments. Mini-SSPedi can be used for children 6-7 years of age. |
| first_indexed | 2024-04-12T07:17:21Z |
| format | Article |
| id | doaj.art-8e41361e87734abc8954d43a69c76ff1 |
| institution | Directory Open Access Journal |
| issn | 1471-2407 |
| language | English |
| last_indexed | 2024-04-12T07:17:21Z |
| publishDate | 2022-07-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj.art-8e41361e87734abc8954d43a69c76ff12022-12-22T03:42:26ZengBMCBMC Cancer1471-24072022-07-012211910.1186/s12885-022-09814-8Reliability and validity of proxy-SSPedi and mini-SSPedi in pediatric patients 2-7 years receiving cancer treatmentsDeborah Tomlinson0L. Lee Dupuis1Donna L. Johnston2Susan Kuczynski3Serina Patel4Tal Schechter5Emily Vettese6Mark Mairs7George A. Tomlinson8Lillian Sung9Program in Child Health Evaluative Sciences, The Hospital for Sick Children, Peter Gilgan Centre for Research and LearningProgram in Child Health Evaluative Sciences, The Hospital for Sick Children, Peter Gilgan Centre for Research and LearningDivision of Hematology/Oncology, Children’s Hospital of Eastern OntarioOntario Parents Advocating for Children with Cancer (OPACC)Division of Haematology/Oncology, Department of Pediatrics, London Health Sciences CentreDivision of Haematology/Oncology, The Hospital for Sick ChildrenProgram in Child Health Evaluative Sciences, The Hospital for Sick Children, Peter Gilgan Centre for Research and LearningProgram in Child Health Evaluative Sciences, The Hospital for Sick Children, Peter Gilgan Centre for Research and LearningDepartment of Medicine, Toronto General HospitalProgram in Child Health Evaluative Sciences, The Hospital for Sick Children, Peter Gilgan Centre for Research and LearningAbstract Background Symptom Screening in Pediatrics Tool (SSPedi) was developed for symptom screening by children 8-18 years. Objectives were to evaluate the reliability and validity of proxy-SSPedi and self-report mini-SSPedi for younger children. Methods This multi-center study enrolled guardians of children 2-7 years receiving cancer treatments (proxy-SSPedi) and their children 4-7 years (mini-SSPedi). The two populations were: (1) More symptomatic group where children were receiving active cancer treatment and were in hospital or clinic for four consecutive days; and (2) Less symptomatic group where children were receiving maintenance therapy for acute lymphoblastic leukemia or had completed cancer therapy. Proxy-SSPedi or mini-SSPedi were completed with measures of mucositis, nausea, pain, quality of life and overall symptoms. Respondents in the more symptomatic group repeated proxy-SSPedi/mini-SSPedi and a global symptom change scale 3 days later. Results There were 402 guardians and 326 children included in the analysis. Test re-test reliability of proxy-SSPedi showed intraclass correlation coefficient (ICC) 0.83 (95% confidence interval (CI) 0.72-0.90). Mean difference in proxy-SSPedi between more and less symptomatic groups was 9.7 (95% CI 8.3-11.1). Proxy-SSPedi was responsive to change and hypothesized relationships between measures were observed. With a priori threshold ≥0.6, inter-rater ICC among all dyads and those 6-7 years were 0.54 (95% CI 0.45-0.62) and 0.62 (95% CI 0.50-0.71) respectively. Among participating children, other hypothesized reliability and validity thresholds were generally met. Conclusions Proxy-SSPedi is reliable, valid and responsive in children 2-7 years old receiving cancer treatments. Mini-SSPedi can be used for children 6-7 years of age.https://doi.org/10.1186/s12885-022-09814-8Symptom screeningChildrenValidityReliabilityResponsivenessProxy |
| spellingShingle | Deborah Tomlinson L. Lee Dupuis Donna L. Johnston Susan Kuczynski Serina Patel Tal Schechter Emily Vettese Mark Mairs George A. Tomlinson Lillian Sung Reliability and validity of proxy-SSPedi and mini-SSPedi in pediatric patients 2-7 years receiving cancer treatments BMC Cancer Symptom screening Children Validity Reliability Responsiveness Proxy |
| title | Reliability and validity of proxy-SSPedi and mini-SSPedi in pediatric patients 2-7 years receiving cancer treatments |
| title_full | Reliability and validity of proxy-SSPedi and mini-SSPedi in pediatric patients 2-7 years receiving cancer treatments |
| title_fullStr | Reliability and validity of proxy-SSPedi and mini-SSPedi in pediatric patients 2-7 years receiving cancer treatments |
| title_full_unstemmed | Reliability and validity of proxy-SSPedi and mini-SSPedi in pediatric patients 2-7 years receiving cancer treatments |
| title_short | Reliability and validity of proxy-SSPedi and mini-SSPedi in pediatric patients 2-7 years receiving cancer treatments |
| title_sort | reliability and validity of proxy sspedi and mini sspedi in pediatric patients 2 7 years receiving cancer treatments |
| topic | Symptom screening Children Validity Reliability Responsiveness Proxy |
| url | https://doi.org/10.1186/s12885-022-09814-8 |
| work_keys_str_mv | AT deborahtomlinson reliabilityandvalidityofproxysspediandminisspediinpediatricpatients27yearsreceivingcancertreatments AT lleedupuis reliabilityandvalidityofproxysspediandminisspediinpediatricpatients27yearsreceivingcancertreatments AT donnaljohnston reliabilityandvalidityofproxysspediandminisspediinpediatricpatients27yearsreceivingcancertreatments AT susankuczynski reliabilityandvalidityofproxysspediandminisspediinpediatricpatients27yearsreceivingcancertreatments AT serinapatel reliabilityandvalidityofproxysspediandminisspediinpediatricpatients27yearsreceivingcancertreatments AT talschechter reliabilityandvalidityofproxysspediandminisspediinpediatricpatients27yearsreceivingcancertreatments AT emilyvettese reliabilityandvalidityofproxysspediandminisspediinpediatricpatients27yearsreceivingcancertreatments AT markmairs reliabilityandvalidityofproxysspediandminisspediinpediatricpatients27yearsreceivingcancertreatments AT georgeatomlinson reliabilityandvalidityofproxysspediandminisspediinpediatricpatients27yearsreceivingcancertreatments AT lilliansung reliabilityandvalidityofproxysspediandminisspediinpediatricpatients27yearsreceivingcancertreatments |